FIELD: pharmacology.
SUBSTANCE: invention relates to compounds of formula : 
, wherein X1 is N or CR11; X2 is N or CR13; Z is NR7R8 or CR7R8R14; Each of R1, R5, R9 and R10 is independently H or C1-C6 alkyl optionally substituted with one or more substituents selected from the group consisting of halogen and hydroxyl; Each of R2, R3 and R4 is independently -Q1-T1, wherein Q1 is a bond or a C1-C3 alkyl linker optionally substituted with halogen and T1 is H, halogen, hydroxyl or RS1, wherein RS1 is C1-C3 alkyl, C3-C8 cycloalkyl and RS1 is optionally substituted with one or more substituents selected from the group consisting of halogen and hydroxyl; R6 is C6-C10 aryl or a 5- or 6-membered heteroaryl containing 1 or 2 heteroatoms independently selected from N, O and S, each of which is optionally substituted with one or more -Q2-T2, wherein Q2 is a bond or C1 -C3 alkyl linker optionally substituted with halogen, and T2 is H, halogen, -NRaRb or RS2, wherein each of Ra and Rb is independently H or RS3, each of RS2 and RS3 is independently C1-C6alkyl, or 4-12 Membered heterocycloalkyl having 1 or 2 heteroatoms independently selected from N and O or Ra and Rb form together with N atom, to which they are attached, 4-12 membered heterocycloalkyl ring containing the heteroatom N and optionally containing 0 or 1 additional heteroatom selected from N or O; R7 is -Q4-T4 wherein Q4 is a bond or a C1-C4 alkyl linker optionally substituted with halogen and T4 is H or RS4 wherein each RS4 is C1-C6 alkyl, C3-C8 cycloalkyl or 4-12 membered heterocycloalkyl Containing one heteroatom selected from O or N and each of RS4 is optionally substituted with one or more -Q5-T5, wherein Q5 is a bond and T5 is H, halogen, C1-C6 alkyl, amino or mono-C1-C6alkylamino; Each of R8, R11, R12 and R13 is independently H, halogen, hydroxyl or RS6, wherein RS6 is C1-C6 alkyl or C3-C8 cycloalkyl, a 4- to 12-membered heterocycloalkyl containing 1 or 2 heteroatoms; or R7 and R8 form together with the N atom to which they are attached a 4-11 membered heterocycloalkyl ring containing 0-2 additional heteroatoms or R7 and R8 form together with the atom C to which they are attached a 4-11 membered A heterocycloalkyl ring containing from 1 to 3 heteroatoms; And R14 is absent or is H or C1-C6 alkyl optionally substituted with halogen, or a pharmaceutically acceptable salt thereof.
EFFECT: compounds are used to treat cancer.
61 cl, 12 dwg, 7 tbl, 201 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SUBSTITUTED BENZENE COMPOUNDS | 2012 |
|
RU2629118C2 |
| TREATMENT METHOD | 2012 |
|
RU2621148C2 |
| SUBSTITUTED BENZENE COMPOUNDS | 2013 |
|
RU2658919C2 |
| COMPOUNDS | 2016 |
|
RU2725616C2 |
| AMIDES OF CONDENSED PIPERIDINE AS MODULATORS OF ION CHANNELS | 2014 |
|
RU2741810C2 |
| BICYCLIC LACTAMS AND METHODS FOR USE THEREOF | 2016 |
|
RU2716136C2 |
| 1,3-BENZODIOXOLE DERIVATIVE | 2015 |
|
RU2679131C2 |
| HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | 2018 |
|
RU2797822C2 |
| TRANSGLUTAMINASE 2 (TG2) INHIBITORS | 2019 |
|
RU2781370C2 |
| PYRROLOPYRAZINE KINASE INHIBITORS | 2012 |
|
RU2673064C2 |
